

Pensa Pharma has been awarded a prize for its “Best development and commercialization of generic medicines”

Barcelona, April 9, 2019.- Pensa Pharma (PENSA), a company of the ESTEVE Group specialized in generic medicines, has been awarded a prize at the II edition of La Razón Comunidad Valenciana Awards. Specifically, PENSA has received the award for “*Best development and commercialization of generic medicines*”.

The prize is a recognition for the work and commitment of PENSA, a Spanish company founded in 2006, to the research and development of new products that benefit both consumers and health care professionals and, at the same time, contribute to the rationalization of health care resources and the sustainability of the health care system, and, in this case, in the specific field of generic medicines.

PENSA has a wide range of generic drugs that comprises practically all therapeutic areas to meet the health professionals’ needs for prescribing and dispensing medicines and, above all, to meet the patients’ needs. Currently the company has a presence in Europe and the United States, strictly complying with the quality standards required by the European and American markets.

The prize “*Best development and commercialization of generic medicines*” has been collected by Fadel Elchichini, Country Manager at PENSA, at a ceremony that took place at the hotel SH Valencia Palace, and which was attended by the President of the Autonomous Region of Valencia, Ximo Puig.

About Pensa Pharma

Pensa Pharma (PENSA) was set up in 2006, with a clear purpose to become a reference in the generics industry internationally. It already has subsidiaries in Italy, Turkey, Portugal and the USA. Being part of the pharmaceutical group ESTEVE, PENSA specializes in the development, manufacturing and marketing of generic medicines, with the aim of offering the maximum number of molecules to favor better access to treatments and, thus, contributing to an optimization and rationalization of health care resources in a more efficient way.

For more information contact:

Olga Cajal, Communication ESTEVE, Tel. 93 446 62 60, ocajal@esteve.com

M^a José Egea, Atrevia, Tel. 93 410 06 30, mjegea@atrevia.com